Iovance Biotherapeutics, Inc. Common Stock
IOVAStock
$4.66+144.33%52W
Market Cap$1.96B
P/E—
Div yield—
Beta0.70
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)61.66%
Price vs S&P 500 (4W)23.49%
VGM Score70.90
Market Capitalization$1.96B
Earnings Surprise History
Q1 26-0.19est. -0.15
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
3.94
3.94
4.00
4.00
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
IOVAIovance Biotherapeutics, Inc. Common Stock | C | B | A | $4.66 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Iovance Biotherapeutics is a biopharmaceutical company developing autologous TIL (tumor-infiltrating lymphocyte) cell therapies for solid tumors. The company's personalized approach harnesses patients' own immune cells to target and destroy cancer cells. Iovance is advancing toward U.S. regulatory approval and commercialization of what could be the first autologous T-cell therapy for solid tumor cancers.